Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity

被引:61
作者
Ahmed, HH
Mannaa, F
Elmegeed, GA [1 ]
Doss, SH
机构
[1] Natl Res Ctr, Hormones Dept, Giza, Egypt
[2] Natl Res Ctr, Dept Med Physiol, Giza, Egypt
关键词
melatonin; cardioprotective; doxorubicin; derivatives;
D O I
10.1016/j.bmc.2004.10.066
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed at evaluation of melatonin and some of its novel synthesized derivatives 3, 4, 9 and 10b as cardioprotective agents against doxorubicin-induced acute cardiac toxicity in rats. Also, this work was extended to study the potential role of each synthesized derivative in comparison with the parent compound melatonin. Intraperitoneal injection of a single dose (15 mg/kg B.W.) of doxorubicin resulted in significant increase in serum troponin 1, leptin, triglycerides, cholesterol and LDL-cholesterol levels with concomitant decrease in serum T3, T4 and IL-1alpha levels. In contrast, intraperitoneal injection of melatonin or its synthesized derivatives especially compounds 3 and 10b in a dose of 5 mg/kg B.W./day for 10 days reversed doxorubicin-induced changes in the above mentioned parameters towards the normal values. The present data revealed that doxorubicin exerts its action mainly through the oxidative stress. This appeared from the significant elevation in serum nitric oxide level and cardiac lipid peroxidation level with concomitant decrease in cardiac antioxidative enzymes activity. Treatment with melatonin and its derivatives 3 and 10b could reduce the markers of oxidative stress and restore the activity of the antioxidative enzymes in the heart tissue. In conclusion, the cardioprotective effect of melatonin and its derivatives may be mediated through the antioxidant and free radical scavenging activity of these compounds. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1847 / 1857
页数:11
相关论文
共 78 条
  • [1] AEBI H, 1984, METHOD ENZYMOL, V105, P121
  • [2] Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques
    Aggarwal, A
    Schneider, DJ
    Terrien, EF
    Sobel, BE
    Dauerman, HL
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (01) : 6 - 9
  • [3] AREND WP, 1997, IMMUNOLOGIST, V5, P197
  • [4] Arola OJ, 2000, CANCER RES, V60, P1789
  • [5] Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings
    Bertinchant, JP
    Polge, A
    Juan, JM
    Oliva-Lauraire, MC
    Giuliani, I
    Marty-Double, C
    Burdy, JY
    Fabbro-Peray, P
    Laprade, M
    Bali, JP
    Granier, C
    de la Coussaye, JE
    Dauzat, M
    [J]. CLINICA CHIMICA ACTA, 2003, 329 (1-2) : 39 - 51
  • [6] BODOR GS, 1994, J CLIN IMMUNOASSAY, V17, P40
  • [7] DAVIES KJA, 1986, J BIOL CHEM, V261, P3060
  • [8] Dobosz Maria, 2003, Acta Pol Pharm, V60, P41
  • [9] Doss SH, 2003, PHARMAZIE, V58, P607
  • [10] MELATONIN RECEPTORS - ARE THERE MULTIPLE SUBTYPES
    DUBOCOVICH, ML
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (02) : 50 - 56